Glucose and insulin suppression of plasma free fatty acids in obese subjects with normal glucose tolerance or mild, newly diagnosed type 2 (non-insulin-dependent) diabetes

J Endocrinol Invest. 1990 Jan;13(1):55-9. doi: 10.1007/BF03348582.

Abstract

The in vivo suppressive effect of glucose and insulin on plasma free fatty acid concentrations was investigated in obese subjects with (n = 6) and without (n = 6) Type 2 (non-insulin-dependent) diabetes mellitus during a 4h-hyperglycemic glucose clamp (about 11.2 mmol/l). Somatostatin was infused (250 micrograms/h) during the third h of glucose clamp to inhibit glucose-stimulated insulin secretion. Plasma insulin values were similar in the two groups at fasting and all throughout the study (F = 0.04; p = NS, two way analysis of variance), while the amount of glucose metabolized during the clamp was lower in diabetic subjects. Plasma free fatty acid concentrations, which were similar in the two groups at fasting, decreased during hyperglycemia and glucose-induced hyperinsulinemia (0-120 min; 180-240 min), and rose during hyperglycemia and somatostatin-inhibited insulin secretion (120-180 min). However, plasma free fatty acid concentrations were significantly higher in diabetic subjects all along the study period both in absolute terms (F = 11.4; p less than 0.0001) and when individual data were recalculated as percent of fasting value (F = 13.3; p less than 0.0001). Our data suggest that suppressibility of fasting plasma free fatty acids is lower in obese Type 2 diabetes in comparison with obese non-diabetic subjects.

MeSH terms

  • Adult
  • Analysis of Variance
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications
  • Fatty Acids, Nonesterified / blood*
  • Female
  • Glucose / physiology*
  • Glucose Clamp Technique
  • Glucose Tolerance Test
  • Humans
  • Insulin / physiology*
  • Male
  • Middle Aged
  • Obesity / blood*
  • Obesity / complications
  • Somatostatin

Substances

  • Fatty Acids, Nonesterified
  • Insulin
  • Somatostatin
  • Glucose